» Articles » PMID: 22932790

Aspergillus Tracheobronchitis: Report of 8 Cases and Review of the Literature

Overview
Specialty General Medicine
Date 2012 Aug 31
PMID 22932790
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Aspergillus tracheobronchitis (AT) is an infrequent but severe form of invasive pulmonary aspergillosis in which the fungal infection is entirely or predominantly confined to the tracheobronchial tree. We reviewed 8 cases of AT diagnosed in our tertiary care center during an 18-year period, as well as 148 cases previously reported in the English literature from 1985 to July 2011. The demographic, clinical, imaging, bronchoscopic, and outcome characteristics of every eligible patient were excerpted, and predictors of inhospital mortality were identified by logistic regression. Solid organ transplantation (SOT) (44.2%), hematologic malignancy (21.2%), neutropenia (18.7%), and chronic obstructive pulmonary disease (15.4%) were the most common underlying conditions reported. Most cases occurred in patients receiving long-term corticosteroid treatment (71.8%) or chemotherapy (25.0%). Fever and respiratory complaints (cough, dyspnea, stridor, or wheezing) were the most frequent symptoms; one-third of patients developed acute respiratory distress at presentation, and 15.1% were asymptomatic at the time of diagnosis. Initial imaging studies were not informative in 47.4% of the cases. Aspergillus fumigatus was the predominant species (74.4%). The pseudomembranous form was the most commonly observed (31.9% of cases) and was more frequent in neutropenic patients (p = 0.007), whereas ulcerative AT (31.2%) was associated with SOT (p = 0.001). The most frequent antifungal monotherapy regimens were amphotericin B deoxycholate (23.1%) and itraconazole (18.6%), whereas combined therapy was administered in 35.9% of the cases. Overall inhospital mortality was 39.1%, with neutropenia (odds ratio [OR], 20.47; p < 0.001) and acute respiratory distress at presentation (OR, 9.54; p = 0.002) as independent prognostic factors. Our pooled analysis of the literature shows that AT remains a rare opportunistic infection with a nonspecific presentation and a variable course depending on the nature of the predisposing factor.

Citing Articles

Pseudomembranous Aspergillus tracheobronchitis: A Rare Manifestation of Invasive Aspergillosis in a Immunocompetent Patient.

Xu X, Ye C, Li N, Yu X, Liao Y, Shen Y Infect Drug Resist. 2025; 18:1297-1302.

PMID: 40059942 PMC: 11890357. DOI: 10.2147/IDR.S495620.


Tracheobronchitis With Mediastinal Lymphadenopathy in a Patient With Well-Controlled HIV Infection.

Singhatiraj E, Tiengburanatarm K, Pongpirul K Case Rep Infect Dis. 2024; 2024:9748358.

PMID: 39629056 PMC: 11614518. DOI: 10.1155/crdi/9748358.


Invasive Tracheobronchial Aspergillosis: A Fatal Complication in a Patient With Treated Mediastinal Lung Adenocarcinoma.

Ikeda T, Yanagihara T, Chen M, Sanai R, Osaki Y, Kikushima M Cureus. 2024; 16(9):e70024.

PMID: 39445303 PMC: 11498964. DOI: 10.7759/cureus.70024.


Clinical presentations and diagnostic approaches of pediatric necrotizing tracheobronchitis with influenza A virus and Staphylococcus aureus co-infections.

Hu C, Zhang N, Xu D, Chen Z, Yu J, Yang Z Sci Rep. 2024; 14(1):20880.

PMID: 39242687 PMC: 11379925. DOI: 10.1038/s41598-024-71867-5.


AWMF mold guideline "Medical clinical diagnostics for indoor mold exposure" - Update 2023 AWMF Register No. 161/001.

Hurrass J, Heinzow B, Walser-Reichenbach S, Aurbach U, Becker S, Bellmann R Allergol Select. 2024; 8:90-198.

PMID: 38756207 PMC: 11097193. DOI: 10.5414/ALX02444E.